According to data from The Cancer Genome Atlas (TCGA), EZR expression is significantly decreased in colon cancer, with downregulation observed in 78% of colon adenocarcinoma (COAD) cases and 25% of rectal adenocarcinoma (READ) cases. Here, EZR is linked to malignant colon neoplasm.